The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Atevirdine     [4-(3-ethylaminopyridin-2- yl)piperazin-1...

Synonyms: CHEMBL280527, SureCN356038, DNC011520, U-87201, AC1L1U1S, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Atevirdine mesylate

  • Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E [1].
  • Additional studies should be done to determine the role of atevirdine in the therapy for HIV infection [2].
 

Psychiatry related information on Atevirdine mesylate

 

High impact information on Atevirdine mesylate

 

Chemical compound and disease context of Atevirdine mesylate

 

Biological context of Atevirdine mesylate

 

Anatomical context of Atevirdine mesylate

 

Gene context of Atevirdine mesylate

 

Analytical, diagnostic and therapeutic context of Atevirdine mesylate

References

  1. Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E. Althaus, I.W., Chou, J.J., Gonzales, A.J., Deibel, M.R., Chou, K.C., Kezdy, F.J., Romero, D.L., Aristoff, P.A., Tarpley, W.G., Reusser, F. J. Biol. Chem. (1993) [Pubmed]
  2. Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team. Reichman, R.C., Morse, G.D., Demeter, L.M., Resnick, L., Bassiakos, Y., Fischl, M., Para, M., Powderly, W., Leedom, J., Greisberger, C. J. Infect. Dis. (1995) [Pubmed]
  3. Pilot study of the efficacy of atevirdine in the treatment of AIDS dementia complex. Brew, B.J., Dunbar, N., Druett, J.A., Freund, J., Ward, P. AIDS (1996) [Pubmed]
  4. Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections. Morse, G.D., Fischl, M.A., Shelton, M.J., Borin, M.T., Driver, M.R., DeRemer, M., Lee, K., Wajszczuk, C.P. Antimicrob. Agents Chemother. (1996) [Pubmed]
  5. Drug interactions with antiviral drugs. Taburet, A.M., Singlas, E. Clinical pharmacokinetics. (1996) [Pubmed]
  6. Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals. Been-Tiktak, A.M., Williams, I., Vrehen, H.M., Richens, J., Aldam, D., van Loon, A.M., Loveday, C., Boucher, C.A., Ward, P., Weller, I.V., Borleffs, J.C. Antimicrob. Agents Chemother. (1996) [Pubmed]
  7. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine. Campbell, T.B., Young, R.K., Eron, J.J., D'Aquila, R.T., Tarpley, W.G., Kuritzkes, D.R. J. Infect. Dis. (1993) [Pubmed]
  8. In-vitro selection of HIV-1 variants resistant to non-nucleoside reverse transcriptase inhibitors in monocyte-derived macrophages. Been-Tiktak, A.M., de Haas, C.J., de Graaf, L., Boucher, C.A., Verhoef, J., Borleffs, J.C., Nottet, H.S., Schuurman, R. J. Antimicrob. Chemother. (1997) [Pubmed]
  9. Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients. Been-Tiktak, A.M., Vrehen, H.M., Schneider, M.M., van der Feltz, M., Branger, T., Ward, P., Cox, S.R., Harry, J.D., Borleffs, J.C. Antimicrob. Agents Chemother. (1995) [Pubmed]
  10. In vitro protein-binding characteristics of atevirdine and its N-dealkylated metabolite. Rosser, L.M., O'Donnell, A.M., Lee, K.M., Morse, G.D. Antiviral Res. (1994) [Pubmed]
  11. Absorption, distribution, metabolism, and excretion of atevirdine in the rat. Chang, M., Sood, V.K., Wilson, G.J., Kloosterman, D.A., Sanders, P.E., Schuette, M.R., Judy, R.W., Voorman, R.L., Maio, S.M., Slatter, J.G. Drug Metab. Dispos. (1998) [Pubmed]
  12. Sensitive reversed-phase high-performance liquid chromatographic method for the determination of atevirdine and its N-desethyl metabolite in human saliva or cerebrospinal fluid using solid-phase extraction. Howard, G.M., Schwende, F.J. J. Chromatogr. B Biomed. Sci. Appl. (1997) [Pubmed]
  13. Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients. Demeter, L.M., Meehan, P.M., Morse, G., Fischl, M.A., Para, M., Powderly, W., Leedom, J., Holden-Wiltse, J., Greisberger, C., Wood, K., Timpone, J., Wathen, L.K., Nevin, T., Resnick, L., Batts, D.H., Reichman, R.C. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1998) [Pubmed]
  14. Cerebral perfusion scanning in treating AIDS dementia: a pilot study. Szeto, E.R., Freund, J., Brew, B.J., Loder, A., Griffiths, M.R. J. Nucl. Med. (1998) [Pubmed]
 
WikiGenes - Universities